EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

# Curriculum Vitae

## Personal information

Marjolijn Schalk

## Work experience

1. Employer: Kreatech Diagnostics
   - Start date: 03-1998
   - End date: 08-2000
   - Position: R&D employee
   - Activities: Development of human diagnostics based on molecular biological techniques
   - Country: Netherlands
2. Employer: National Institute for Public Health _ Centre for Biological Medicines
   - Start date: 08-2000
   - End date: 12-2007
   - Position: Scientific officer
   - Activities: Batch release of vaccins and blood products (OMCL) Development of molecular biological techniques for quality control of gene therapeutics and vaccins
   - Country: Netherlands
3. Employer: National Institute for Public Health _ Centre for Zoonotic Diseases and Environmental Microbiology
   - Start date: 01-2008
   - End date: 11-2015
   - Position: Scientific officer
   - Activities: Coordination of research on transmission of pathogens from the environment to humans (eg. Legionella, enteroviruses)
   - Country: Netherlands
4. Employer: Medicines Evaluation Board
   - Start date: 12-2015
   - End date: 10-2019
   - Position: Regulatory Project Leader
   - Activities: Coordination of registration of human medicines via the centralised and decentralised procedures
   - Country: Netherlands
5. Employer: Medicines Evaluation Board
   - Start date: 11-2019
   - End date:
   - Position: Quality assessor biotechnological pharmaceuticals
   - Activities: Assessment of Module 3 of biotechnological pharmaceuticals
   - Country: Netherlands

## Education and training

1. Subject: Wageningen University
   - Start date: 08-1987
   - End date: 08-1993
   - Qualification: Master of science
   - Organisation: Molecular Sciences, Molecular biology, Cell biology, Biochemistry
   - Country: Netherlands
2. Subject: Wageningen University
   - Start date: 09-1993
   - End date: 03-1999
   - Qualification: Physical Degree
   - Organisation: Genetics, Molecular Biology, Cell biology
   - Country:

## Additional information

### Publications

1: de Rooij MMT, Hoek G, Schmitt H, Janse I, Swart A, Maassen CBM, Schalk M, Heederik DJJ, Wouters IM. Insights into Livestock_Related Microbial Concentrations in Air at Residential Level in a Livestock Dense Area. Environ Sci Technol. 2019 May 13.

2: van Heijnsbergen E, van Deursen A, Bouwknegt M, Bruin JP, de Roda Husman AM, Schalk JA. Presence and Persistence of Viable, Clinically Relevant Legionella pneumophila Bacteria in Garden Soil in the Netherlands. Appl Environ Microbiol.2016 Aug 15;82(17):5125_31.

3: van Heijnsbergen E, Schalk JA, Euser SM, Brandsema PS, den Boer JW, de Roda Husman AM. Confirmed and Potential Sources of Legionella Reviewed. Environ Sci Technol. 2015 Apr 21;49(8):4797_815.

4: Schalk JA, Euser SM, van Heijnsbergen E, Bruin JP, den Boer JW, de Roda Husman AM. Soil as a source of Legionella pneumophila sequence type 47. Int J Infect Dis. 2014 Oct;27:18_9.

5: van Heijnsbergen E, de Roda Husman AM, Lodder WJ, Bouwknegt M, Docters van Leeuwen AE, Bruin JP, Euser SM, den Boer JW, Schalk JA. Viable Legionella pneumophila bacteria in natural soil and rainwater puddles. J Appl Microbiol. 2014 Sep;117(3):882_90.

6: Kułdo JM, Ásgeirsdóttir SA, Zwiers PJ, Bellu AR, Rots MG, Schalk JA, Ogawara KI, Trautwein C, Banas B, Haisma HJ, Molema G, Kamps JA. Targeted adenovirus mediated inhibition of NF_κB_dependent inflammatory gene expression in endothelial cells in vitro and in vivo. J Control Release. 2013 Feb 28;166(1):57_65.

7: Bouwknegt M, Schijven JF, Schalk JA, de Roda Husman AM. Quantitative risk estimation for a Legionella pneumophila infection due to whirlpool use. Risk Anal. 2013 Jul;33(7):1228_36.

8: Schalk JA, Docters van Leeuwen AE, Lodder WJ, de Man H, Euser S, den Boer JW, de Roda Husman AM. Isolation of Legionella pneumophila from pluvial floods by amoebal coculture. Appl Environ Microbiol. 2012 Jun;78(12):4519_21.

9: Schalk JA, de Vries CG, Orzechowski TJ, Rots MG. A rapid and sensitive assay for detection of replication_competent adenoviruses by a combination of microcarrier cell culture and quantitative PCR. J Virol Methods. 2007 Nov;145(2):89_95.

10: Kooter IM, Pennings JL, Fokkens PH, Leseman DL, Boere AJ, Gerlofs_Nijland ME, Cassee FR, Schalk JA, Orzechowski TJ, Schaap MM, Breit TM, Dormans JA, van Oostrom CT, de Vries A, van Steeg H. Ozone induces clear cellular and molecular responses in the mouse lung independently of the transcription_coupled repair status. J Appl Physiol (1985). 2007 Mar;102(3):1185_92.

11: Gommans WM, McLaughlin PM, Schalk JA, Groothuis GM, Haisma HJ, Rots MG. Highly efficient and carcinoma_specific adenoviral replication restricted by the EGP_2 promoter. J Control Release. 2007 Jan 22;117(1):1_10.

12: Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgönne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin. 2006 Mar_Apr;2(2):45_53.

13: Rots MG, Elferink MG, Gommans WM, Oosterhuis D, Schalk JA, Curiel DT, Olinga P, Haisma HJ, Groothuis GM. An ex vivo human model system to evaluate specificity of replicating and non_replicating gene therapy agents. J Gene Med. 2006 Jan;8(1):35_41.

14: Schalk JA, de Vries CG, Jongen PM. Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay. Biologicals. 2005 Jun;33(2):71_9.

15: Schalk JA, van den Elzen C, Ovelgönne H, Baas C, Jongen PM. Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real_time PCR. J Virol Methods. 2004 May;117(2):179_87.

16: Heetebrij RJ, Talman EG, v Velzen MA, van Gijlswijk RP, Snoeijers SS, Schalk M, Wiegant J, v d Rijke F, Kerkhoven RM, Raap AK, Tanke HJ, Reedijk J, Houthoff HJ. Platinum(II)_based coordination compounds as nucleic acid labeling reagents: synthesis, reactivity, and applications in hybridization assays. Chembiochem. 2003 Jul 7;4(7):573_83.

17: van Leeuwen W, Libregts C, Schalk M, Veuskens J, Verbrugh H, van Belkum A. Binary typing of Staphylococcus aureus strains through reversed hybridization using digoxigenin_universal linkage system_labeled bacterial genomic DNA. J Clin Microbiol. 2001 Jan;39(1):328_31.

18: Schalk JA, Offenberg HH, Peters E, Groot NP, Hoovers JM, Heyting C. Isolation and characterization of the human SCP2 cDNA and chromosomal localization of the gene. Mamm Genome. 1999 Jun;10(6):642_4.

19: Schalk JA, Dietrich AJ, Vink AC, Offenberg HH, van Aalderen M, Heyting C. Localization of SCP2 and SCP3 protein molecules within synaptonemal omplexes of the rat. Chromosoma. 1998 Dec;107(8):540_8.

20: Offenberg HH, Schalk JA, Meuwissen RL, van Aalderen M, Kester HA, Dietrich AJ, Heyting C. SCP2: a major protein component of the axial elements of synaptonemal complexes of the rat. Nucleic Acids Res. 1998 Jun 1;26(11):2572_9.

## Projects

## Memberships

Expert at the European Microbiology Expert group of the European Commission

Expert European Pharmacopoeia Working group gene therapeutics

## Other Relevant Information